Statement from the National Cancer Institute providing information regarding treatment of cancer patients and participation in clinical trials during the COVID-19 pandemic.
A new study offers insight into genetic alterations associated with osteosarcoma, the most common bone tumor of children and adolescents, and the findings have implications for genetic testing of children with osteosarcoma and their families.
An NCI clinical trial finds the drug selumetinib improves outcomes for children with neurofibromatosis type 1 (NF1), shrinking inoperable tumors called plexiform neurofibromas, reducing pain, and improving function and overall quality of life.
The 2020 Annual Report to the Nation on the Status of Cancer finds overall cancer death rates continue to decline in the United States for all cancer sites combined. A companion study looked at Healthy People 2020 targets for four common cancers.
Testing for prostate cancer with a combined biopsy method led to more accurate diagnosis and prediction of the course of the disease in an NCI study. The method is poised to reduce the risk of prostate cancer overtreatment and undertreatment.
For children and young adults with certain relapsed B-cell acute lymphoblastic leukemia (B-ALL), the immunotherapy drug blinatumomab is superior to standard chemotherapy, an NCI-sponsored Children’s Oncology Group trial shows.
Nearly half of phase 3 cancer clinical trials carried out by the NCI-sponsored SWOG Cancer Research Network were associated with clinical care guidelines or new drug approvals, a study in JAMA Network Open shows.
Findings from a new NCI study of patients who received radioactive iodine (RAI) treatment for hyperthyroidism show an association between the dose of treatment and long-term risk of death from solid cancers, including breast cancer.
The 2019 Annual Report to the Nation on the Status of Cancer finds overall cancer death rates continue to decline and cancer incidence dropped in men and remained stable in women. A special section reports on recent cancer trends in younger adults.
An NCI-led study shows rates for aggressive subtypes of uterine cancer rose rapidly among women ages 30 to 79 from 2000–2015. The findings, published in the Journal of Clinical Oncology, also reveal racial disparities in incidence and survival rates.